Advertisement
U.S. markets close in 3 hours 9 minutes

  • S&P 500

    5,622.18
    +26.42 (+0.47%)
    ?

  • Dow 30

    41,378.58
    +281.81 (+0.69%)
    ?

  • Nasdaq

    17,659.99
    +90.32 (+0.51%)
    ?

  • Russell 2000

    2,180.07
    +50.65 (+2.38%)
    ?

  • Crude Oil

    69.07
    +0.10 (+0.14%)
    ?

  • Gold

    2,609.90
    +29.30 (+1.14%)
    ?

  • Silver

    31.14
    +1.03 (+3.43%)
    ?

  • EUR/USD

    1.1084
    +0.0007 (+0.07%)
    ?

  • 10-Yr Bond

    3.6500
    -0.0300 (-0.82%)
    ?

  • GBP/USD

    1.3126
    +0.0002 (+0.01%)
    ?

  • USD/JPY

    140.8340
    -1.0030 (-0.71%)
    ?

  • Bitcoin USD

    59,413.98
    +1,508.33 (+2.60%)
    ?

  • XRP USD

    0.57
    +0.01 (+2.44%)
    ?

  • FTSE 100

    8,273.09
    +32.12 (+0.39%)
    ?

  • Nikkei 225

    36,581.76
    -251.51 (-0.68%)
    ?

Merck stock falls on Summit cancer drug's trial results

In this article:

Merck & Co. (MRK) shares tick lower in the red on Monday after a trial found Summit Therapeutics' (SMMT) lung cancer treatment drug ivonescimab to show better results than Merck's Keytruda. Market Domination's Julie Hyman and Josh Lipton break down this news.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written and updated by Luke Carberry Mogan.

Advertisement